The safety and efficacy of adalimumab for patients with moderately to severely active ulcerative colitis (UC) has been reported up to Week 52 from the placebo-controlled trials ULTRA (Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab) 1 and 2. Up to 4 years of data for adalimumab-treated patients from ULTRA 1, 2, and the open-label extension ULTRA 3 are presented.

READ FULL ARTICLE Curated publisher From Nature